Randomized Controlled Trial
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. May 15, 2023; 15(5): 878-891
Published online May 15, 2023. doi: 10.4251/wjgo.v15.i5.878
Table 2 Overall adenoma detection rate in patients of the two group

IEE group (n = 2113)
WLI group (n = 2098)
P value
Relative risk (95%CI)
ADR508/2113 (24.0)458/2098 (21.8)0.091.10 (0.99-1.23)
Advanced ADR127/2113 (6.0)116/2098 (5.5)0.501.09 (0.85-1.39)
Diminutive ADR323/2113 (15.3)286/2098 (13.6)0.131.12 (0.97-1.30)
ADR in different ages
< 50 yr67/586 (11.4)54/557 (9.7)0.341.18 (0.84-1.66)
≥ 50 yr441/1527 (28.9)404/1541 (26.2)0.101.10 (0.98-1.24)
ADR in different gender
Male288/1002 (28.7)254/982 (25.9)0.151.11 (0.96-1.28)
Female220/1111 (19.8)204/1116 (18.3)0.361.08 (0.91-1.29)
ADR with different indications
Diagnostic
< 50 yr26/270 (9.6)23/256 (9.0)0.801.07 (0.63-1.83)
≥ 50 yr179/610 (29.3)166/620 (26.8)0.321.10 (0.92-1.31)
Surveillance
< 50 yr9/104 (8.7)7/93 (7.5)0.771.15 (0.45-2.97)
≥ 50 yr138/509 (27.1)126/508 (24.8)0.401.09 (0.89-1.5)
Screening
< 50 yr32/212 (15.1)24/208 (11.5)0.281.31 (0.80-2.14)
≥ 50 yr124/408 (30.4)112/413 (27.1)0.301.12 (0.90-1.39)
Withdrawal time7.90 ± 3.427.85 ± 3.470.30